ERBB2 and non-small cell lung carcinoma: Although HER2 overexpressing NSCLC cell lines exhibit intrinsic resistance to chemotherapy, particularly to platinum containing regimens107, in many prospective clinical trials including patients with NSCLC, HER2 amplification or overexpression has not correlated with response to conventional chemotherapy108.